Skip to main content

Drug Interactions between medroxyprogesterone and olaparib

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

medroxyPROGESTERone olaparib

Applies to: medroxyprogesterone and olaparib

Consumer information for this interaction is not currently available.

ADDITIONAL CONTRACEPTION RECOMMENDED: In vitro data suggest a theoretical potential for olaparib to decrease the plasma concentrations of hormonal contraceptives. Olaparib has been shown in vitro to induce several CYP450 isoenzymes, which may cause increased metabolism of contraceptive hormones. However, olaparib also inhibits CYP450 3A4 in vitro and is predicted to be a mild in vivo inhibitor of CYP450 3A4, the isoenzyme that is primarily responsible for the metabolic clearance of contraceptive hormones. Clinical data regarding this interaction and its potential impact on the efficacy of hormonal contraceptives are currently lacking.

MANAGEMENT: Until more information is available, some authorities recommend that an additional non-hormonal contraceptive method be considered during treatment with olaparib. For women with hormone-dependent cancer, two non-hormonal contraceptive methods should be considered. Findings in animal reproductive studies as well as its mechanism of action suggest olaparib may have teratogenic and genotoxic potential and could cause embryofoetal harm when administered to a pregnant woman, thus it is particularly important that female patients not become pregnant during treatment. All women of childbearing potential must use reliable contraception before starting olaparib, during treatment, and for 6 months after receiving the last dose of olaparib, unless abstinence is the chosen method of contraception. Two highly effective and complementary forms of contraception are typically recommended. A pregnancy test should be performed on all women of childbearing potential prior to treatment, at regular intervals during treatment, and six months after receiving the last dose. Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed. Intrauterine systems are unlikely to be significantly affected because of their local action.

Drug and food interactions

Major

olaparib food

Applies to: olaparib

Do not consume grapefruit, grapefruit juice, or Seville oranges during treatment with olaparib. Doing so can significantly increase the blood levels of olaparib and increase the risk and/or severity of side effects such as nausea, vomiting, diarrhea, indigestion, loss of appetite, abdominal pain or discomfort, lung problems, and impaired bone marrow function resulting in low numbers of different types of blood cells. You may also be more likely to develop anemia, bleeding problems, or infections due to low blood cell counts. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.